Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | RORC | P51449 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4539298 | 0.87 | NAMPT (0.52) | NAMPTCYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL5019822 | 0.87 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL5019830 | 0.80 | KMT2A (0.42) | CYP3A4CYP2C9CYP2C19RORCKMT2A | |
| SCHEMBL15646494 | 0.78 | NAMPT (0.55) | NAMPTCYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL15647056 | 0.78 | NAMPT (0.58) | NAMPTCYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL15647080 | 0.78 | NAMPT (0.56) | NAMPTCYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL15645101 | 0.77 | NAMPT (0.51) | NAMPTCYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL15646599 | 0.75 | NAMPT (0.52) | NAMPTCYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL15645336 | 0.74 | NAMPT (0.57) | NAMPTCYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL12693125 | 0.74 | GAA (0.47) | CYP3A4CYP2C9CYP2C19KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | NAMPT 3662/4885CYP3A4 595/4885CYP2C9 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.